News

Eli Lilly and Company and Incyte announced results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial…
Read More...

Context Therapeutics, a clinical-stage women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and…
Read More...

AbbVie announced that it has submitted applications seeking approval for SKYRIZI (risankizumab-rzaa, 150 mg) to the U.S. Food and Drug Administration (FDA) and for SKYRIZI …
Read More...

Icosavax, Inc. announced the close of a $100 million Series B Financing, led by RA Capital Management and joined by Janus Henderson Investors, Perceptive Advisors, Viking Global…
Read More...

CytoDyn Inc. a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced it has executed an…
Read More...

AIM ImmunoTech Inc. announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, reporting no serious…
Read More...

AB Science SA together with the University of Chicago, announces the signing of an exclusive licensing agreement for conducting research on the prevention and treatment of humans…
Read More...

Eli Lilly and Company and Incyte announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for…
Read More...

Progenity, Inc. a biotechnology company with an established track record of success developing and commercializing molecular testing products, announced an agreement with Ionis…
Read More...

MyBiotics Pharma Ltd., a microbiome therapeutics company, and Hadasit Medical Research Services and Development Ltd., the technology transfer office of Hadassah Medical Center,…
Read More...

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced…
Read More...

Sound Pharmaceuticals, Inc. (SPI) is pleased to announce a Cooperative Grant award from the National Center for Advancing Translational Sciences (NCATS) at the NIH for $3.1M to support…
Read More...

AB Science SA together with the University of Chicago, announces the signing of an exclusive licensing agreement for conducting research on the prevention and treatment of humans…
Read More...

Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel drug target discovery and development of novel therapeutics, announced the execution of a global…
Read More...

Antengene Corporation Limited a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class…
Read More...

Cidara Therapeutics, Inc. a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections,…
Read More...

Sorrento Therapeutics, Inc. announced the signing of a merger agreement pursuant to which Sorrento will acquire ACEA Therapeutics, Inc. (“ACEA”). The acquisition will include late…
Read More...

Novavax, Inc. a biotechnology company developing next-generation vaccines for serious infectious diseases, announced the initiation of crossover arms in two ongoing clinical trials of…
Read More...

Anixa Biosciences, Inc. a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced that based on Proof of Concept (POC) animal study…
Read More...

Innovation Pharmaceuticals announced that an independent Data Monitoring Committee (DMC) completed its scheduled review of interim safety data in the Company’s randomized, double-blind,…
Read More...